UCB Biopharma initiates SLC6A1-NDD natural history study to inform future clinical trials
UCB Biopharma has launched a prospective longitudinal study to evaluate the natural history of SLC6A1-NDD.
Asset / Drug
Drug and asset intelligence for UCB with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.